GO:0004660 protein farnesyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004660 protein farnesyltransferase activity catalyzes the transfer of a farnesyl group from (2E,6E)-farnesyl diphosphate to a cysteine residue in a C-terminal CAAX motif of a protein.
• The enzyme is a heterodimer of FNTA (alpha subunit) and FNTB (beta subunit) and is a validated drug target in cancer and parasitic diseases [1,3,8].
• Protein farnesyltransferase activity is required for the membrane localization and function of RAS-family GTPases and many other CAAX proteins.
• Inhibition of protein farnesyltransferase activity has potent antimalarial and antiparasitic effects, making it a promising target for neglected tropical diseases [3,5,6,8].
• Protein farnesyltransferase activity also regulates HDAC6 activity in a microtubule-dependent manner, linking it to cytoskeletal dynamics and protein acetylation.
• Quantitative assays for cellular farnesyltransferase activity enable determination of the minimum substrate reactivity for biologically relevant protein farnesylation.
Description
Protein farnesyltransferase activity (GO:0004660) is a molecular function that attaches a 15-carbon farnesyl isoprenoid group to the cysteine residue of a C-terminal CAAX motif in target proteins. This post-translational modification, known as protein farnesylation, increases the hydrophobicity of the modified protein and promotes its association with cellular membranes, which is essential for the biological activity of many signaling proteins, including RAS-family GTPases. The reaction is catalyzed by a heterodimeric enzyme composed of an alpha subunit (FNTA) and a beta subunit (FNTB), and it uses (2E,6E)-farnesyl diphosphate as the isoprenoid donor. Because farnesylation is critical for the function of oncogenic RAS and other disease-associated proteins, protein farnesyltransferase activity has been extensively studied as a therapeutic target in cancer and parasitic infections [1,3,8]. Researchers investigating this activity rely on enzymatic assays, cell-based farnesylation reporters, and genetic models to dissect its roles in cell signaling, cytoskeletal regulation, and disease [2,4,7].
protein farnesyltransferase activity At A Glance
| GO ID | GO:0004660 |
|---|---|
| GO term | protein farnesyltransferase activity |
| Ontology | molecular_function |
| Synonym | CAAX farnesyltransferase activity; farnesyl-diphosphate:protein-cysteine farnesyltransferase activity; FTase activity; protein-cysteine farnesyltransferase activity |
| Major function | Transfer of a farnesyl group from farnesyl diphosphate to a cysteine residue in a CAAX motif of a protein substrate |
| Reaction | L-cysteinyl-[protein] + (2E,6E)-farnesyl diphosphate = S-(2E,6E)-farnesyl-L-cysteinyl-[protein] + diphosphate |
| Enzyme composition | Heterodimer of FNTA (alpha subunit) and FNTB (beta subunit) |
| Substrate motif | C-terminal CAAX motif (C = cysteine, A = aliphatic amino acid, X = any amino acid) |
| Inhibitor classes | Peptidomimetic and small-molecule farnesyltransferase inhibitors (FTIs) [1,5,6] |
What Is GO:0004660?
Protein farnesyltransferase activity (GO:0004660) is defined as the catalysis of the reaction: L-cysteinyl-[protein] + (2E,6E)-farnesyl diphosphate = S-(2E,6E)-farnesyl-L-cysteinyl-[protein] + diphosphate. In other words, it is the enzyme activity that transfers a farnesyl group from farnesyl diphosphate to a cysteine residue of a protein substrate, forming a thioether-linked farnesyl-cysteine adduct and releasing diphosphate. This activity is synonymous with CAAX farnesyltransferase activity, farnesyl-diphosphate:protein-cysteine farnesyltransferase activity, FTase activity, and protein-cysteine farnesyltransferase activity.
Why Is protein farnesyltransferase activity Important in Cell Biology?
Protein farnesyltransferase activity is essential for the proper localization and function of a wide range of CAAX proteins, including RAS-family GTPases, and its dysregulation contributes to cancer and other diseases. Because farnesylation is required for the oncogenic activity of mutant RAS, farnesyltransferase inhibitors (FTIs) were developed as anticancer agents and have been evaluated in clinical trials. Beyond cancer, protein farnesyltransferase activity is a validated target in parasitic protozoa, where inhibitors exhibit potent antimalarial and antiparasitic activity [3,5,6,8]. The activity also regulates HDAC6 in a microtubule-dependent manner, implicating it in cytoskeletal dynamics and protein acetylation. Quantitative assays of cellular farnesyltransferase activity are therefore critical for understanding the minimum substrate reactivity required for biologically relevant protein farnesylation.
• Required for membrane targeting and signaling of RAS-family GTPases, which are frequently mutated in cancer.
• Validated drug target in cancer, with farnesyltransferase inhibitors evaluated in clinical trials.
• Potent antimalarial and antiparasitic activity of protein farnesyltransferase inhibitors highlights its role in infectious disease [3,5,6,8].
• Regulates HDAC6 activity in a microtubule-dependent manner, linking farnesylation to cytoskeletal regulation.
• Enables quantitative determination of the minimum substrate reactivity for biologically relevant protein farnesylation.
• Provides a 96-well format assay for high-throughput measurement of enzymatic activity.
• Involved in the post-translational modification of numerous CAAX proteins beyond RAS, affecting diverse cellular processes.
• Represents a paradigm for studying isoprenoid transferases and their substrate specificity [1,7].
• Offers a target for antiparasitic drug development with improved membrane permeability [5,6].
• Supports research on protein prenylation in cell signaling, trafficking, and cytoskeletal organization.
What Happens During protein farnesyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme first grabs the protein that needs to be modified and the farnesyl molecule that will be attached.
Protein farnesyltransferase recognizes substrate proteins that end with a CAAX motif, where C is a cysteine, A is usually an aliphatic amino acid, and X determines whether the protein is farnesylated or geranylgeranylated. The enzyme binds both the protein substrate and the isoprenoid donor (2E,6E)-farnesyl diphosphate in an ordered manner, positioning the cysteine thiol for nucleophilic attack.
Catalytic transfer of the farnesyl group
In simple terms: The enzyme snips off the farnesyl group from its carrier and glues it onto the cysteine of the target protein.
The catalytic mechanism involves the transfer of the farnesyl group from farnesyl diphosphate to the sulfur atom of the cysteine in the CAAX motif, forming a stable thioether bond and releasing diphosphate. This reaction is catalyzed by the beta subunit (FNTB) of the heterodimeric enzyme, while the alpha subunit (FNTA) contributes to substrate binding and overall stability.
Post-farnesylation processing
In simple terms: After the farnesyl tag is attached, the protein gets trimmed and modified further to help it stick to membranes.
Following farnesylation, the C-terminal -AAX tripeptide is proteolytically removed, and the newly exposed farnesyl-cysteine is methylated by isoprenylcysteine carboxyl methyltransferase (ICMT). These processing steps increase the hydrophobicity of the protein and enhance its association with cellular membranes, which is required for the biological function of many CAAX proteins.
Membrane association and signaling
In simple terms: The farnesyl tag acts like a sticky anchor that pulls the protein to the cell membrane where it can do its job.
The farnesyl group inserts into lipid bilayers, anchoring the modified protein to the plasma membrane and other organelle membranes. This membrane localization is essential for the signaling activity of RAS-family GTPases and for the function of other CAAX proteins involved in cell growth, differentiation, and cytoskeletal regulation [1,2].
Regulation by cellular context
In simple terms: The enzyme's activity can be influenced by the cell's state and by other proteins it interacts with.
Protein farnesyltransferase activity is regulated by the availability of its substrates and by interactions with other cellular proteins. For example, the enzyme regulates HDAC6 activity in a microtubule-dependent manner, indicating that its function is integrated with cytoskeletal dynamics and protein acetylation pathways. Quantitative assays have been developed to measure cellular farnesyltransferase activity and define the minimum substrate reactivity for biologically relevant farnesylation.
Key Genes Involved in GO:0004660 protein farnesyltransferase activity
The following genes and proteins are central to protein farnesyltransferase activity (GO:0004660) and its biological functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FNTA | Alpha subunit of protein farnesyltransferase | Essential for enzyme stability and substrate binding; target for structural studies |
| FNTB | Beta subunit of protein farnesyltransferase | Catalytic subunit; target of farnesyltransferase inhibitors |
| HRAS | Small GTPase; farnesylation required for membrane localization | Oncogene frequently mutated in cancer; model substrate for farnesylation studies |
| KRAS | Small GTPase; farnesylation required for membrane localization | Oncogene; farnesylation inhibitors tested in cancer |
| NRAS | Small GTPase; farnesylation required for membrane localization | Oncogene; model for farnesylation-dependent signaling |
| RHO | Small GTPase; farnesylation regulates cytoskeletal dynamics | Involved in cell migration and cytoskeletal organization |
| RAC1 | Small GTPase; farnesylation affects membrane targeting | Regulates actin cytoskeleton and cell migration |
| HDAC6 | Histone deacetylase 6; activity regulated by farnesyltransferase | Links farnesylation to microtubule-dependent processes |
| ICMT | Isoprenylcysteine carboxyl methyltransferase | Catalyzes post-farnesylation methylation; part of CAAX processing |
| RCE1 | Ras converting CAAX endopeptidase 1 | Removes -AAX tripeptide after farnesylation |
| PGGT1B | Geranylgeranyltransferase type I beta subunit | Related prenyltransferase with distinct substrate specificity |
| RABGGTA | Rab geranylgeranyltransferase alpha subunit | Related prenyltransferase involved in Rab protein modification |
| CHM | Rab escort protein 1 | Facilitates geranylgeranylation of Rab proteins |
| PDE6D | Prenyl-binding protein delta | Binds farnesylated proteins and regulates trafficking |
| RASGRP1 | Ras guanyl releasing protein 1 | Farnesylated protein involved in Ras signaling |
| PTPN11 | Protein tyrosine phosphatase non-receptor type 11 | Farnesylation affects localization and signaling |
| CENPE | Centromere protein E | Farnesylated kinesin involved in mitosis |
| LAMIN B | Nuclear lamina protein | Farnesylation required for nuclear envelope integrity |
How Is protein farnesyltransferase activity Regulated?
Protein farnesyltransferase activity is regulated at multiple levels. The availability of farnesyl diphosphate, a product of the mevalonate pathway, directly influences enzyme activity. Substrate availability and the expression levels of FNTA and FNTB also modulate activity. Additionally, the enzyme interacts with regulatory proteins and is subject to post-translational modifications that affect its localization and function. The activity is integrated with cellular signaling pathways, as demonstrated by its role in regulating HDAC6 in a microtubule-dependent manner. Quantitative assays have been developed to measure cellular farnesyltransferase activity and to define the minimum substrate reactivity required for biologically relevant protein farnesylation.
protein farnesyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HRAS | Cancer (RAS-driven tumors) | Knockout or point-mutation cell lines to study farnesylation-dependent signaling |
| KRAS | Cancer (pancreatic, lung, colorectal) | Knock-in of oncogenic KRAS with or without farnesylation site mutation |
| FNTB | Cancer; parasitic infections | Knockout or knockdown to assess sensitivity to farnesyltransferase inhibitors [1,3] |
| HDAC6 | Neurodegeneration; cytoskeletal disorders | Overexpression or knockout to study microtubule-dependent regulation |
| Plasmodium falciparum FTase | Malaria | Parasite-specific knockout or inhibitor-treated cultures [3,5,6,8] |
Cancer
Protein farnesyltransferase activity is required for the membrane localization and oncogenic signaling of mutant RAS proteins, which are among the most frequently mutated oncogenes in human cancer. Farnesyltransferase inhibitors (FTIs) were developed to block this activity and have been evaluated in clinical trials for various malignancies. Although FTIs showed limited single-agent efficacy in RAS-mutant tumors, they remain an active area of research, particularly in combination therapies and for cancers driven by other farnesylated proteins.
Parasitic infections
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity against Plasmodium falciparum, the causative agent of malaria [3,8]. Peptidomimetic inhibitors with improved membrane permeability have shown in vitro and in vivo antimalarial efficacy. Further optimization by introducing N-benzylimidazole moieties has led to highly improved antiparasitic activity, highlighting protein farnesyltransferase as a promising target for neglected tropical diseases.
Cytoskeletal and neurodegenerative disorders
Protein farnesyltransferase activity regulates HDAC6 in a microtubule-dependent manner, linking it to cytoskeletal dynamics and protein acetylation. Dysregulation of HDAC6 and microtubule function has been implicated in neurodegenerative diseases and cancer, suggesting that modulating farnesyltransferase activity could have therapeutic potential beyond oncology.
From protein farnesyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of farnesyltransferase activity affect RAS membrane localization? | FNTA or FNTB knockout cell lines |
| Can a point mutation in the CAAX motif prevent farnesylation? | Point-mutation knock-in of HRAS/KRAS CAAX cysteine to serine |
| Does farnesylation regulate HDAC6 activity? | Knockout or overexpression of FNTB with HDAC6 activity assays |
| What is the minimum substrate reactivity for farnesylation? | Tagged knock-in of substrate proteins with quantitative farnesylation assays |
| Can farnesyltransferase inhibitors block parasite growth? | Overexpression of parasite FTase in Plasmodium cultures [3,5,6,8] |
| Does farnesylation affect protein trafficking? | Knock-in of fluorescently tagged CAAX proteins for imaging |
How to Study the protein farnesyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Scintillation proximity assay | Transfer of radiolabeled farnesyl group to protein substrate | High-throughput screening of farnesyltransferase inhibitors |
| Quantitative cellular farnesylation assay | Minimum substrate reactivity for farnesylation | Determining biologically relevant protein farnesylation |
| In vitro enzyme kinetics | Catalytic rate and substrate affinity | Characterizing enzyme mechanism and inhibitor potency |
| Cell-based reporter assay | Farnesylation-dependent membrane localization | Evaluating inhibitors in living cells |
| Antimalarial growth inhibition assay | Parasite growth in presence of inhibitors | Testing antimalarial activity of farnesyltransferase inhibitors [3,5,6,8] |
| HDAC6 activity assay | Deacetylase activity in response to farnesyltransferase modulation | Studying microtubule-dependent regulation |
| Mass spectrometry | Identification of farnesylated proteins | Proteomic profiling of CAAX proteins |
| Fluorescence microscopy | Subcellular localization of farnesylated proteins | Imaging membrane association |
Enzymatic activity assays
Protein farnesyltransferase activity can be measured using a 96-well format assay with scintillation counting, which quantifies the transfer of radiolabeled farnesyl groups to protein substrates. This method is suitable for high-throughput screening of inhibitors and for determining enzyme kinetics.
Quantitative cellular farnesylation assays
Cellular farnesyltransferase activity can be quantitatively determined using reporter proteins or mass spectrometry-based approaches to define the minimum substrate reactivity for biologically relevant protein farnesylation. These assays are useful for studying substrate specificity and for evaluating the efficacy of farnesyltransferase inhibitors in cells.
Inhibitor screening and characterization
Farnesyltransferase inhibitors can be screened and characterized using in vitro enzymatic assays and cell-based assays [1,5,6]. Peptidomimetic inhibitors with improved membrane permeability have been tested for antimalarial activity in vitro and in vivo, and N-benzylimidazole-containing inhibitors have shown improved antiparasitic activity.
Genetic and pharmacological perturbation
Knockout, knockdown, or overexpression of FNTA and FNTB, combined with farnesyltransferase inhibitors, allows researchers to dissect the cellular functions of protein farnesyltransferase activity [1,2]. These approaches can be coupled with imaging and biochemical assays to assess effects on membrane localization, signaling, and cytoskeletal dynamics [1,2].
How CRISPR Can Be Used to Study GO:0004660 protein farnesyltransferase activity
Knockout
CRISPR knockout of FNTA or FNTB eliminates protein farnesyltransferase activity, allowing researchers to study the consequences of loss of farnesylation on RAS signaling, membrane localization, and cell viability. Knockout cell lines are valuable for validating the specificity of farnesyltransferase inhibitors and for identifying cellular pathways that depend on this activity.
Point Mutation
CRISPR point mutation can be used to introduce specific amino acid substitutions in the CAAX motif of substrate proteins, such as replacing the critical cysteine with serine, to prevent farnesylation. This approach enables precise dissection of the role of farnesylation in protein function without affecting other prenylation pathways.
Knock-in
CRISPR knock-in of tagged or mutant versions of FNTA, FNTB, or substrate proteins allows for real-time tracking of farnesylation and its effects on protein localization and function. Tagged knock-in models can be used with imaging and biochemical assays to study the dynamics of protein farnesylation in living cells.
Overexpression
CRISPR-mediated overexpression of FNTA and FNTB or of farnesylated substrate proteins can be used to enhance farnesyltransferase activity and study its effects on cell signaling and transformation. Overexpression models are also useful for testing the efficacy of farnesyltransferase inhibitors under conditions of elevated enzyme activity.
How EDITGENE Supports protein farnesyltransferase activity Research
Researchers studying protein farnesyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in farnesylation-dependent processes, such as RAS membrane localization, HDAC6 regulation, or parasite growth. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for protein farnesyltransferase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CHURC1-FNTB Knockout HEK293 Cell Line | EDJ-KQ52500 | Human | 100529261 | Details Get a Quote |
| CHURC1-FNTB Knockout HeLa Cell Line | EDJ-KQ60963 | Human | 100529261 | Details Get a Quote |
| CHURC1-FNTB Knockout A-549 Cell Line | EDJ-KQ69438 | Human | 100529261 | Details Get a Quote |
| CHURC1-FNTB Knockout HCT 116 Cell Line | EDJ-KQ77789 | Human | 100529261 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
Frequently Asked Questions About protein farnesyltransferase activity
What is protein farnesyltransferase activity?
Protein farnesyltransferase activity (GO:0004660) is the enzyme activity that transfers a farnesyl group from farnesyl diphosphate to a cysteine residue in a CAAX motif of a protein substrate, forming a farnesyl-cysteine adduct and releasing diphosphate.
What genes are involved in protein farnesyltransferase activity?
The core genes are FNTA (alpha subunit) and FNTB (beta subunit), which form the heterodimeric enzyme. Substrate genes include HRAS, KRAS, NRAS, RHO, RAC1, and many other CAAX-containing proteins.
What is the reaction catalyzed by protein farnesyltransferase?
The reaction is: L-cysteinyl-[protein] + (2E,6E)-farnesyl diphosphate = S-(2E,6E)-farnesyl-L-cysteinyl-[protein] + diphosphate.
Why is protein farnesyltransferase a drug target?
It is required for the membrane localization and oncogenic activity of RAS proteins, making it a target for anticancer therapy, and it is also essential for the survival of malaria parasites, making it a target for antimalarial drugs [1,3,8].
How is protein farnesyltransferase activity measured?
It can be measured using a 96-well scintillation proximity assay that quantifies the transfer of radiolabeled farnesyl groups to protein substrates, or by quantitative cellular farnesylation assays [4,7].
What diseases are associated with protein farnesyltransferase activity?
It is associated with cancer (RAS-driven tumors), malaria, and other parasitic infections. It also regulates HDAC6 in a microtubule-dependent manner, linking it to cytoskeletal and neurodegenerative disorders [1,2,3,5,6,8].
What are farnesyltransferase inhibitors?
Farnesyltransferase inhibitors (FTIs) are compounds that block protein farnesyltransferase activity. They include peptidomimetic and small-molecule inhibitors that have been tested as anticancer and antiparasitic agents [1,5,6].
How does protein farnesyltransferase regulate HDAC6?
Protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner, meaning that farnesylation influences HDAC6 function through microtubule dynamics.
What is the CAAX motif?
The CAAX motif is a C-terminal tetrapeptide sequence (C = cysteine, A = aliphatic amino acid, X = any amino acid) that directs proteins for farnesylation or geranylgeranylation.
Can CRISPR be used to study protein farnesyltransferase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the roles of FNTA, FNTB, and substrate proteins in farnesylation-dependent processes.
Conclusion
Protein farnesyltransferase activity (GO:0004660) is a critical enzymatic function that mediates the post-translational attachment of farnesyl groups to CAAX-containing proteins, thereby controlling their membrane localization and biological activity. Its central role in RAS signaling, cancer, and parasitic infections has made it a major focus of drug discovery, with farnesyltransferase inhibitors showing potent antimalarial and anticancer potential [1,3,5,6,8]. The activity also regulates HDAC6 in a microtubule-dependent manner, expanding its relevance to cytoskeletal and neurodegenerative research. Quantitative assays and CRISPR-based models continue to advance our understanding of the minimum substrate reactivity and cellular functions of protein farnesylation.
References
- 1. Ayral-Kaloustian S et al.. 2002. Protein farnesyltransferase inhibitors.. Curr Med Chem 9(10):1003-32 PMID: 12733981
- 2. Zhou J et al.. 2009. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.. J Biol Chem 284(15):9648-55 PMID: 19228685
- 3. Nallan L et al.. 2005. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.. J Med Chem 48(11):3704-13 PMID: 15916422
- 4. Harwood HJ Jr. 1995. Protein farnesyltransferase: measurement of enzymatic activity in 96-well format using TopCount microplate scintillation counting technology.. Anal Biochem 226(2):268-78 PMID: 7793628
- 5. Carrico D et al.. 2004. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability.. Bioorg Med Chem 12(24):6517-26 PMID: 15556768
- 6. Bosc D et al.. 2016. Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.. Eur J Med Chem 109:173-86 PMID: 26774924
- 7. Flynn SC et al.. 2014. Quantitative determination of cellular farnesyltransferase activity: towards defining the minimum substrate reactivity for biologically relevant protein farnesylation.. Chembiochem 15(15):2205-10 PMID: 25182009
- 8. Sharma K. 2017. A Review on Plasmodium falciparum-Protein Farnesyltransferase Inhibitors as Antimalarial Drug Targets.. Curr Drug Targets 18(14):1676-1686 PMID: 27557819
